<p><strong>Our Library never stops expanding. What are the most recent contributions to LabRulezGCMS Library in the week of 14th September 2026? Check out new documents from the field of the gas phase, especially GC and GC/MS techniques!</strong></p><blockquote><p><span style="font-size:20px;">👉 </span><a target="_blank" rel="noopener noreferrer" href="https://gcms.labrulez.com/library"><span style="font-size:20px;"><strong>SEARCH THE LARGEST REPOSITORY OF DOCUMENTS ABOUT GCMS AND RELATED TECHNIQUES</strong></span></a></p></blockquote><blockquote><p><strong>👉 Need info about different analytical techniques?</strong> Peek into <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library"><strong>LabRulezLCMS</strong></a> or <a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/library"><strong>LabRulezICPMS</strong></a> libraries.</p></blockquote><p>This week we bring you application note by <strong>Agilent Technologies, </strong>poster<strong> </strong>by <strong>Shimadzu / AOAC </strong>and brochure by<strong> Thermo Fisher Scientific!</strong></p><h3><strong>1. Agilent Technologies: Analysis of Ethylene Glycol and Diethylene Glycol in Oral Syrup Containing Glycerin</strong></h3><p><strong>Using the Agilent 8890 GC system coupled with the Agilent 5977C GC/MSD</strong></p><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/an_glycol_analysis_gc_ms_5994_9411en_agilent_e9dfb856ce.pdf"><strong>Full PDF for download</strong></a></li></ul><section><div><div><div><div><div><div><p>This study demonstrates the use of an <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/gcms/library?mainauthorItems=10&amp;search=8890"><strong>Agilent 8890 GC system</strong></a> coupled with the <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/gcms/library?mainauthorItems=10&amp;search=5977C"><strong>Agilent 5977C single quadrupole GC/MSD</strong></a> to detect and quantify ethylene glycol (EG) and diethylene glycol (DEG) in oral syrups containing glycerin per United States Food and Drug Administration (USFDA) recommendations.1 Samples were extracted using methanol, filtered through nylon filters, then followed by GC/MS analysis. Instrument Limit of Quantification (iLOQ) of 0.1&nbsp;ppm was achieved using internal standard calibration. A solvent-based calibration range was established from 0.1 to 4&nbsp;ppm.</p><h4><strong>Experimental</strong></h4><h5><strong>GC parameters</strong></h5><ul><li><strong>Inlet Temperature: </strong>240&nbsp;°C&nbsp;</li><li><strong>Analytical Column: </strong>DB-WAX GC column, 30&nbsp;m × 0.25&nbsp;mm, 0.50&nbsp;µm&nbsp;</li><li><strong>Injection Volume:</strong> 1&nbsp;µL&nbsp;</li><li><strong>Column Flow: </strong>Helium; 1.0&nbsp;mL/min, constant flow&nbsp;</li><li><strong>Injection Mode: </strong>Split (20:1)&nbsp;</li><li><strong>Oven Program:</strong> Start at 130&nbsp;°C (hold for 4&nbsp;min), ramp at 17&nbsp;°C/min to 195&nbsp;°C (hold for 4&nbsp;min), then at 35&nbsp;°C/min to 240&nbsp;°C (hold for 4&nbsp;min).&nbsp;</li><li><strong>MS Transfer Line Temperature: </strong>240&nbsp;°C&nbsp;</li></ul><h5><strong>MS Parameters&nbsp;</strong></h5><ul><li><strong>SIM Ions:</strong> 31, 33, 43, 75, 113&nbsp;</li><li><strong>Ion Source Temperature: </strong>230&nbsp;°C&nbsp;</li><li><strong>Quadrupole Temperature (Q1 and Q2):</strong> 150&nbsp;°C</li></ul><h4><strong>Conclusion&nbsp;</strong></h4><p>A sensitive and robust method was optimized for analysis of EG and DEG in oral syrups containing glycerin. The method uses an internal standard calibration using 2,2,2-trichloroethanol. Instrument LOQ was established at 0.1&nbsp;ppm level for both EG and DEG. This method meets the requirements per US FDA recommendations for EG and DEG testing.1 Therefore, this study demonstrates the usefulness of the developed method for routine analysis of oral syrup samples for EG and DEG analysis using GC/MS.</p><h3><strong>2. Shimadzu / AOAC: Investigation of Varietal Classification Method for Coffee Beans Using Aroma Compounds</strong></h3><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/aoac_2026_17_e6687812af.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Common coffee bean species are broadly classified into two types: Coffea arabica (Arabica) and Coffea canephora (Robusta). Among them, Arabica is superior in flavor and is highly favored as a specialty beverage. However, in recent years, there have been multiple reports of products sold claiming to be 100% Arabica while being adulterated with Robusta1) . A reported method for discriminating between the two is the analysis of lipophilic extracts of coffee beans using a benchtop NMR spectrometer1) . This method uses 16- O-Methylcafestol, which is present in Robusta but almost undetectable in Arabica, as a marker. However, it requires complicated pretreatment such as extraction and concentration. Therefore, in this Application News, we investigated a method to discriminate between Arabica and Robusta more easily and rapidly using GC-MS/MS and the statistical analysis software eMSTAT Solution.</p><h4><strong>Methods</strong></h4><h5><strong>Analytical Methods&nbsp;</strong></h5><p>Volatile compounds were concentrated and introduced into the GC-MS using the HS-SPME method and then analyzed under the conditions registered in the <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/gcms/library?mainauthorItems=1&amp;search=Smart+Aroma+Database"><strong>GCMS(/MS) Smart Aroma Database</strong> </a>(Table 2). The <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/gcms/library?mainauthorItems=1&amp;search=GCMS-TQTM8040+NX"><strong>GCMS-TQTM8040 NX</strong></a> and the <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/gcms/library?mainauthorItems=1&amp;search=AOC-6000"><strong>AOC-6000 multifunctional autosampler</strong></a><strong> </strong>system were used as the analytical instruments (Fig. 1). To verify whether rapid analysis is possible, a temperature ramp of 10˚C/min was adopted, and a low-polarity column was used to obtain stable retention times for each compound. Data acquisition was performed in Scan mode or MRM mode, and each sample was analyzed three times.</p><h4><strong>Conclusions&nbsp;</strong></h4><ul><li><strong>Clear Group Separation:</strong> Statistical analysis (PCA and cluster analysis) of data acquired in highly sensitive MRM mode clearly separated the two coffee bean types into distinct groups.&nbsp;</li><li><strong>Successful Discrimination:</strong> Our investigation suggested that the discrimination of Arabica and Robusta coffee beans based on aroma compounds is possible using the GCMS-TQ8040 NX, the Smart Aroma Database, and eMSTAT Solution.&nbsp;</li><li><strong>Intuitive and Comprehensive Workflow:</strong> Using eMSTAT Solution, statistical analysis and the creation of discrimination models can be easily performed without advanced expertise. Additionally, this method provides a comprehensive workflow that allows for the qualitative identification of key compounds contributing significantly to the discrimination</li></ul><h3><strong>3. Thermo Fisher Scientific: On-site gas analysis for ABO Thermo Scientific Antaris FTIR Aviator’s Breathing Oxygen (ABO) Gas Analysis System</strong></h3><ul><li>Brochure</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/on_site_gas_analysis_for_abo_br1828_en_4c3b71b244.pdf"><strong>Full PDF for download</strong></a></li></ul><p>The <strong>Thermo Scientific™ Antaris™ FTIR Aviator’s Breathing Oxygen (ABO) Gas Analysis System</strong> is a rugged, portable system that enables rapid validation of the compressed oxygen used by pilots and crew during flight operations. Use of sophisticated FTIR spectroscopic analysis enables detection of common contaminants that may be present due to the manufacturing process— contaminants such as methane, acetylene, and CFC/HCFC can be readily spotted and identified. The instrument’s sturdy design and FTIR spectroscopy’s ability to quantify multiple compounds in a single analysis make the Antaris ABO Analyzer a robust, readily deployable solution for validating the quality of aviator breathing oxygen.</p><h4><strong>Antaris FTIR Aviator’s Breathing Oxygen (ABO) Analyzer at a glance:</strong></h4><ul><li><strong>Components measured:</strong> Up to 25 components can be measured simultaneously, including freons, hydrocarbons, carbon monoxide, and carbon dioxide&nbsp;</li><li><strong>Sample type:</strong> Gas&nbsp;</li><li><strong>Dimensions:</strong> 51 in. (H) x 30.25 in. (W) x 41.5 in. (D)&nbsp;</li><li><strong>Weight:</strong> 240 kg&nbsp;</li><li><strong>Optional accessories:</strong> Purge gas generator, uninterruptible power supply, oxygen analyzer&nbsp;</li><li><strong>Voltage: </strong>120/240V</li></ul></div></div></div></div></div></div></section>

News from LabRulezGCMS Library - Week 38, 2026

<p><strong>Our Library never stops expanding. What are the most recent contributions to LabRulezLCMS Library in the week of 14th September 2026? Check out new documents from the field of liquid phase, especially HPLC and LC/MS techniques!</strong></p><blockquote><p><span style="font-size:20px;">👉 </span><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library"><span style="font-size:20px;"><strong>SEARCH THE LARGEST REPOSITORY OF DOCUMENTS ABOUT LCMS AND RELATED TECHNIQUES</strong></span></a></p></blockquote><blockquote><p><strong>👉 Need info about different analytical techniques?</strong> Peek into <a target="_blank" rel="noopener noreferrer" href="https://gcms.labrulez.com/library"><strong>LabRulezGCMS</strong></a> or <a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/library"><strong>LabRulezICPMS</strong></a> libraries.</p></blockquote><p>This week we bring you application notes by <strong>Agilent Technologies </strong>and <strong>Waters Corporation </strong>and posters by <strong>Shimadzu / AOAC </strong>and<strong> Thermo Fisher Scientific / Metabolomics!</strong></p><h3><strong>1. Agilent Technologies: Improved Analysis of Intact Proteins and Peptides by Reversed Phase HPLC Using the Altura Ultra Inert PLRP-S 1000 Å Column</strong></h3><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/an_altura_ultrainert_column_HPLC_analysis_5994_9322en_agilent_2b3a542647.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Intact protein analysis by reversed-phase HPLC (RP-LC) plays a vital role in quality control for determining the purity of biotherapeutic proteins and improving the identification and quantification of critical quality attributes (CQAs). When coupled to mass spectrometric detection, it allows several things. First, an accurate molecular weight to be determined; second, the identification of variants containing post‑translational modifications (PTMs) and proteoforms; and third, the antibody-to-drug ratio in the case of antibody drug conjugates (ADCs).<sup>1</sup>&nbsp;</p><p>While many RP columns have a silica-based stationary phase to enable broader functionalization, residual acidic silanol groups can interact with basic residues in peptides, proteins, and other biomolecules, resulting in significant peak tailing and loss of chromatographic performance. Polystyrene/divinyl benzene (PS/DVB)-based stationary phases do not contain unintentional adsorption sites. Additionally, larger pore sizes have demonstrated superior chromatographic efficiency through less diffusion restriction into the pore volume and reduction of size exclusion mechanisms, degrading the RP-based selectivity.<sup>2</sup>&nbsp;</p><p>Wide-pore columns like the PLRP-S 1000Å provide an exceptional performance with biomolecules, particularly when combined with MS-compatible mobile phase conditions such as formic acid.&nbsp;</p><p>Even so, some undesirable interactions may be observed when using stainless-steel column hardware. Molecules that possess multiple negative charges (including oligonucleotides, phosphorylated peptides and proteins, and proteins with low isoelectric point in general) may interact with exposed metal ions in stainless-steel column hardware. This can result in the need to "deactivate" new columns by making multiple injections of sample until reproducible results are obtained.&nbsp;</p><p>This application note demonstrates how the new <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/library?mainauthorItems=10&amp;search=Altura+Ultra+Inert"><strong>Altura Ultra Inert </strong></a>PLRP-S 1000 Å column serves as an effective high-performance workhorse in the analysis of large, intact biomolecules. Developed to effectively block nonspecific adsorption during separations, Ultra Inert technology reduced passivation time 15-fold and delivered ~ 10% greater recovery for mAbs and ADCs and up to 100% for smaller biomolecules like GLP-1s and small globular proteins.</p><h4><strong>Experimental</strong></h4><h5><strong>Instrumentation&nbsp;</strong></h5><ul><li>Agilent 1290 Multicolumn thermostat (G7116B)&nbsp;</li><li>Agilent 1290 Bio multisampler (G7137A)&nbsp;</li><li>Agilent 1290 Bio high-speed pump (G7132A)&nbsp;</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/library?mainauthorItems=10&amp;search=6530"><strong>Agilent 6530 Q-TOF MS system</strong></a>&nbsp;</li></ul><h5><strong>Software and data processing&nbsp;</strong></h5><ul><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/library?mainauthorItems=10&amp;search=MassHunter+Workstation"><strong>Agilent MassHunter Workstation, version 10.1&nbsp;</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/library?mainauthorItems=10&amp;search=MassHunter+Qualitative+Analysis"><strong>Agilent MassHunter Qualitative Analysis software, version&nbsp;B.07&nbsp;</strong></a></li><li>Agilent DAR calculator, version B01.01</li></ul><h4><strong>Conclusion&nbsp;</strong></h4><p>Intact mass analysis is a critical methodology to determine the purity of biotherapeutics, but due to the chemical complexity of these analytes, nonspecific adsorption from both silica stationary phase and metal column housing can be highly deleterious to separation performance. The Agilent Altura PLRP-S 1000 Å provides a highly robust solution combining the chemical inertness of polystyrene/divinyl benzene stationary phase with the ultra‑inert Altura hardware to dramatically reduce deleterious peak tailing and increase recovery for biotherapeutics. Herein, we see that analyte recovery for both mAbs, ADCs, GLP-1s, and globular proteins are improved versus stainless-steel, while the Altura PLRP-S column is capable of monitoring both quality critical PTMs such as loss of drug payload as well as accurate quantification of ADC DAR.</p><h3><strong>2. Shimadzu / AOAC: Ambient Ionization Mass Spectrometric Detection of Aroma Released During Gummy Chewing</strong></h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/aoac_2026_47_2_34c41f762f.pdf"><strong>Full PDF for download</strong></a></li></ul><p>In recent years, there has been growing interest in evaluating flavor using analytical instrumentation, and retronasal aroma during eating is important. In this study, we proposed an analytical method for measuring retronasal aroma during eating using a single quadrupole mass spectrometer (<a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/library?mainauthorItems=1&amp;search=2050"><strong>LCMS-2050</strong></a>) equipped with an ambient ion source (Dark Current Discharge Ionization : DCDI) without pretreatment.</p><h4><strong>Conclusion</strong></h4><p>We developed a simple method for evaluating retronasal aroma using a single quadrupole mass spectrometer with an ambient ionization source. Ambient ionization mass spectrometry (DCDI LCMS-2050) can rapidly measure retronasal aroma during eating. Time-resolved visualization reveals texture-dependent differences in aroma release dynamics among grape-flavored gummies. It is also expected to lead to the visualization of the marriage between food and alcohol. This approach may facilitate objective evaluation of flavor release during consumption and support product formulation and sensory science.</p><h3><strong>3. Thermo Fisher Scientific / Metabolomics: Orbitrap Tribrid Real-Time similarity searching of mzCloud library for guided unknown characterization of tea metabolites</strong></h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/po_004849_lsms_rtls_tribrid_apex_small_molecule_metabolomics_po004849_na_en_d0d3156065.pdf"><strong>Full PDF for download</strong></a></li></ul><p>In metabolomics LC-MS data is processed to generate a list of detected compounds with a level of confidence in the identity of each compound based on reference data. This reference data may be spectral data and/or retention time information stored in a library or in silico information generated based on fragmentation rules. These annotated compounds are then used to evaluate biological changes between normal and disease states. One of the major hurdles between collected data and coming to reliable conclusions about the biology is the limited number of standards available to build these libraries. It is common to have hundreds to thousands of compounds detected in a data set that have no library match because there is no commercial standard for that unknown. Instead, there is just an elemental formula and matches from a structure database. These structures can be compared using in silico fragmentation techniques to determine which isomers plausibly match the data. MSn data can help reduce the list of possible matches, but without guidance, ddMS3 may not consistently collect data on the most relevant MS2 fragments to accomplish this.&nbsp;</p><p>In this work we use Real-Time Library Search (RTLS) in a ddMS3 method to help guide the instrument in real time to collect the most relevant data for confirming structural matches.</p><h4><strong>Materials and methods</strong></h4><h5><strong>Test method(s)&nbsp;</strong></h5><p>1 μL aliquots were analyzed using a <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/products?category=48&amp;manufacturerItems=3&amp;search=gold"><strong>Thermo Scientific Hypersil GOLD column</strong></a> on a <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/744"><strong>Thermo Scientific Vanquish Horizon UHPLC</strong></a><strong> </strong>coupled with a <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/561"><strong>Thermo Scientific Orbitrap IQ-X Tribrid mass spectrometer</strong></a> and <strong>Thermo Scientific Orbitrap Tribrid Apex Small Molecule mass spectrometer</strong>. RTLS was run in similarity mode using the offline version of <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/1764"><strong>Thermo Scientific mzCloud library</strong></a>.&nbsp;</p><h5><strong>Data analysis&nbsp;</strong></h5><p>Data was processed using <strong>Thermo Scientific Freestyle and </strong><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/1759"><strong>Compound Discoverer software</strong></a><strong>.</strong></p><h4><strong>Conclusions&nbsp;</strong></h4><p>Tea extracts were analyzed using RTLS to find the most similar compound in the offline version of the mzCloud library and trigger MS3 on the highest m/z matching and non-matching fragments. This provided additional information to confirm similarity and provide insight on shared sub-structures to the library compound as well as additional information on the portions of the structure that were unique to the experimental compound.</p><h3><strong>4. Waters Corporation: The Quantification of Glucagon-like Peptide Receptor Agonists (GLP-1 RAs) in Plasma Extracts Using Capillary UHPLC-MS/MS</strong></h3><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/720009537_en_0068921516.pdf"><strong>Full PDF for download</strong></a></li></ul><div><div><section><div><div><div><div><div><div><h5><strong>Benefits&nbsp;</strong></h5><ul><li>10-fold improvement in sensitivity&nbsp;</li><li>Robust methodology for &gt;500 injections&nbsp;</li><li>Reduced solvent usage&nbsp;</li><li>No need for complex nanospray MS source</li></ul><p>Obesity represents, perhaps, the largest healthcare challenge, affecting approximately 1.3 billion people globally, contributing to a diverse range of chronic diseases e.g., metabolic, cardiovascular, muscular skeletal, and multiple cancers.1 The rapid growth of obesity and associated global healthcare costs means there is a critical need for safe effective treatments.2 GLP-1 RA initially developed for type 2 diabetes have shown clinical efficacy as weight loss medicines.2 These drugs mimic the action of gut hormones which regulate energy metabolism and appetite by interacting with the hypothalamus, brain stem etc., resulting in weight loss. The success of these GLP-1 RAs is associated with their on-target efficacy and long duration of action,3 e.g., half-life of semaglutide t½ = 160–180 hours3 cf. 1–2 minutes for human GLP-1.4 The long half-life of these GLP-1 RAs results in low, sub ng/mL plasma levels 48–72 hours after dosing, which requires a high sensitivity bioanalytical assay to accurately quantify the plasma concentrations5 and define the PK elimination phase.&nbsp;</p><p>Tandem quadrupole electrospray ionization (ESI) mass spectrometry, operated in multiple reaction monitoring (MRM) mode, coupled with 2.1 mm ID ultra-high performance liquid chromatography (UHPLC) is the dominant technology platform for quantitative bioanalysis. As next generation GIP/GLP-1 RAs promise to be more potent, resulting in lower dosing levels and plasma levels, there is a need for more sensitive analytical methodologies to support drug metabolism and pharmacokinetics (DMPK) studies. Capillary/nano LC-MS/MS have been extensively employed in proteomics to increase analytical sensitivity and enable small volume analysis.5 This sensitivity increase is derived from a combination of the superior ionization efficiency at low flow rates and analyte concentration due to the smaller column geometry.6 This application note illustrates the use of capillary (300 µm) UHPLC-MS/MS (MRM) to affect 10-fold improvement in GLP-1-RAs peak response in human plasma extracts, and detection limits as low as 20 pg/mL for tirzepatide.</p><h4><strong>Experimental</strong></h4><p>Capillary chromatography was performed on an <strong>ACQUITY™ M-class Chromatography System</strong> connected to a <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/195"><strong>Xevo™ TQ-XS Mass Spectrometer</strong></a> (Waters Corporation, Wilmslow, UK) equipped with a microflow probe. Capillary UHPLC separations were performed on an <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/1952"><strong>ACQUITY Premier Peptide CSH C18</strong></a>, 300 Å, 1.7 µm, 300 µm x 50 mm Chromatography Column.</p><p>MS analysis was performed at unit mass resolution using positive ESI at a capillary voltage of 3.0 kV, with a cone voltage of 32 V. The cone gas flow, desolvation gas flow, and desolvation gas temperature were 50 L/h, 300 L/h and 600 °C, respectively. The data were analyzed using <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/1544"><strong>waters_connect™ Software</strong></a><strong>,</strong> and MRM transitions used to monitored for the MS/MS detection of liraglutide, exenatide, semaglutide and tirzepatide were as follows: liraglutide 938.7 → 1128.4, exenatide 838 → 396, semaglutide 1029.2 → 1238.1, and tirzepatide 1204.2 → 396.2. Data analysis was performed using <strong>MS Quan Software.</strong></p><h4><strong>Conclusion</strong></h4><p>Bioanalysis plays a critical role in the drug discovery and development processes providing data to support DMPK, safety assessment, pharmacokinetics/pharmacodynamics (PK/PD), and clinical development studies. The development of new, more potent medicines, innovating delivery platforms, micro sampling, and new approach methodologies (e.g., organ on a chip) all require greater levels of analytical sensitivity. Capillary scale UHPLCMS/MS offers the potential to improve bioanalytical detection limits up to 10-fold, without the need for long analysis times and complex operation associated with nano spray LC-MS/MS. Here, the application of capillary (300 µm ID) scale chromatography for the detection of GLP-1 RAs in human plasma extracts at levels as low as 20 pg/mL with robustness over 500 injections was demonstrated.</p></div></div></div></div></div></div></section></div></div>

News from LabRulezLCMS Library - Week 38, 2026

<p><strong>Our Library never stops expanding. What are the most recent contributions to LabRulezICPMS Library in the week of 14th September 2026? Check out new documents from the field of spectroscopy/spectrometry and related techniques!</strong></p><blockquote><p><span style="font-size:20px;">👉 </span><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/library"><span style="font-size:20px;"><strong>SEARCH THE LARGEST REPOSITORY OF DOCUMENTS ABOUT SPECTROSCOPY/SPECTROMETRY RELATED TECHNIQUES</strong></span></a></p></blockquote><blockquote><p><strong>👉 Need info about different analytical techniques?</strong> Peek into <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library"><strong>LabRulezLCMS</strong></a> or <a target="_blank" rel="noopener noreferrer" href="https://gcms.labrulez.com/library"><strong>LabRulezGCMS</strong></a> libraries.</p></blockquote><p>This week we bring you technical note by <strong>Agilent Technologies, </strong>application notes by<strong> Metrohm </strong>and <strong>Thermo Fisher Scientific </strong>and poster by<strong> Shimadzu / AOAC!</strong></p><h3><strong>1. Agilent Technologies: Transitioning from the </strong><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=Cary+630"><strong>Agilent Cary 630 FTIR</strong></a><strong> to the </strong><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=Cary+635"><strong>Agilent Cary 635 FTIR Spectrometer</strong></a></h3><p><strong>Demonstrating methodology equivalence for pharmaceutical applications</strong></p><ul><li>Technical note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/te_cary_630_ftir_transition_cary_635_ftir_5994_9408en_agilent_a2ea2ce512.pdf"><strong>Full PDF for download</strong></a><strong>&nbsp;</strong></li></ul><p>Fourier transform infrared (FTIR) spectroscopy is a powerful analytical tool used to analyze a wide variety of materials by interpreting their infrared (IR) wavenumber absorptions. Within pharmaceutical and biopharmaceutical industries, FTIR analysis is integral for material identification and quality assurance of pharmaceutical&nbsp;substances.&nbsp;</p><p>In the pharmaceutical industry, the Agilent Cary 630 FTIR is used for the identification of drug products, incoming goods, and packaging materials, as specified in global pharmacopoeias, and provides quantitative information such as the concentration of components within pharmaceutical formulations.&nbsp;</p><p>Agilent now presents the Cary 635 FTIR spectrometer—an ultracompact, easy-to-use, high-performing, portable FTIR system. With greater IR power, the Cary 635 FTIR features greater detection sensitivity and faster scanning times. With its predecessor's modular design, the Cary 635 FTIR can analyze the same samples with a newly enhanced performance quality and efficiency.&nbsp;</p><p>For users in the pharmaceutical industry who have experience with the Cary 630 FTIR, this technical overview demonstrates the common methodologies and workflows between the Cary 635 FTIR and Cary 630 FTIR spectrometers for pharmaceutical purposes. It will compare the ability of the two instruments to measure and label IR spectra, identify relevant compounds such as active pharmaceutical ingredients (APIs), and quantify substances within commercial&nbsp;formulations.</p><h4><strong>Instrumentation and software&nbsp;</strong></h4><p>For comparison, all three application tests were conducted using the Cary 630 FTIR and Cary 635 FTIR spectrometers with ZnSe optics and equipped with a single-reflection diamond attenuated total reflectance (ATR) accessory. The specific method parameters are outlined within each corresponding application. Both the Cary 635 FTIR and Cary 630 FTIR use Agilent MicroLab software, which provides step-by-step instructions with supporting images to guide users through the entire analytical workflow. Both spectrometers follow the same methods and operational procedures from sample loading to data processing (Figure 1). Results are presented in an easy-to-understand, color-coded format with customizable limits, ensuring a rapid and intuitive data review.</p><h4><strong>Conclusion&nbsp;</strong></h4><p>The comparison presented here of both the Agilent Cary 635 FTIR and Cary 630 FTIR spectrometers demonstrated shared methodologies that produced consistent results across key applications within pharmacopoeia, including spectrum production, compound identification, and substance&nbsp;quantification. Featuring the same modularity, robustness, and ease of use as the Cary 630 FTIR, the Cary 635 FTIR also offers greater sensitivity and signal-to-noise ratio, resulting from an enhanced IR source intensity. Therefore, users operating in regulated environments can confidently upgrade to the Cary 635 FTIR with the understanding that the workflow from the Cary 630 FTIR is directly transferrable, and that their routine analyses will remain consistent and reliable.</p><h3><strong>2. Metrohm: Coconut water analysis by NIRS</strong></h3><p><strong>Determination of Brix, salinity, conductivity, and pH with one instrument</strong></p><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/an_nir_145_download_05589da42d.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Fresh coconut water is the main edible part of the coconut (aside from the coconut meat) and has gained popularity as a health drink in recent years. Multiple factors influence the quality, such as harvesting time, growth location, and storage duration. This poses a challenge for industrial producers to achieve and maintain the desired product quality.&nbsp;</p><p>Testing the properties of coconut water with standard laboratory methods can be challenging, since trained lab personnel are needed. In contrast, near-infrared spectroscopy (NIRS) is fast, chemical-free, and does not require sample preparation. This Application Note explains how NIRS is used for the multiparameter analysis of coconut water. The NIRS solution is easy to use and can be implemented either atline or in a quality control lab.</p><h4><strong>EXPERIMENTAL EQUIPMENT&nbsp;</strong></h4><p>An <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=220&amp;search=OMNIS+NIR"><strong>OMNIS NIR Analyzer </strong></a>Liquid with a 1 mm flowthrough cell (Figure 1) was used to analyze 206 coconut samples from a commercial supplier. In this configuration, a peristaltic pump injects the sample into the flow-through cell, which is inserted into the cuvette holder. The cell is rinsed with water after each measurement.</p><h4><strong>CONCLUSION</strong></h4><p>This Application Note shows the feasibility of using NIR spectroscopy for the quality control of coconut water. The parameters Brix, conductivity, turbidity, pH value, and salinity can be monitored by NIRS in seconds without any sample preparation. The presented setup with a flow-through cell not only simplifies sample handling but also allows full automation when using an OMNIS Sample Robot. In addition to coconut water, the coconut fruit itself can also be analyzed using near-infrared spectroscopy.</p><h3><strong>3. Shimadzu / AOAC: Analysis of Heavy Metals in Baby Food Using ICP-MS</strong></h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/aoac_2026_46_d9c14b32e0.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Babies are more vulnerable to the effects of toxic metals, and baby food therefore requires careful testing. US and EU regulations1)–3) set limits for toxic metals in baby food. This study analyzed five baby foods using the <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=1&amp;search=ICPMS-2040%2F2050"><strong>ICPMS-2040/2050</strong></a> and evaluated spike recovery and long-term stability.</p><h4><strong>Conclusion&nbsp;</strong></h4><p>Elemental analysis of baby food was conducted using ICP-MS.&nbsp;</p><p>We achieved detection limits that met stringent standards. The spike recovery tests provided good results for all samples with different matrices, confirming the validity of the analysis. Additionally, we analyzed 50 samples of infant formula with a high matrix approximately six hours and confirmed good stability.</p><h3><strong>4. Thermo Fisher Scientific: Process Raman as a comprehensive solution for downstream buffer workflow</strong></h3><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/process_raman_as_comprehensive_solution_an1440_en_c8049b8ede.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Raman technology is rapidly gaining interest as a promising Process Analytical Technology (PAT) solution for real-time, non-invasive monitoring and control of downstream biopharma processes, especially for therapeutics like monoclonal antibodies (mAbs) and nucleic acids. Raman measurement, based on the vibration of molecular bonds, is highly specific for identification and quantification, even in complex or interfering matrices.&nbsp;</p><p>As an in-line PAT tool, Raman spectroscopy offers direct and rapid measurement in aqueous phases without sample preparation. These features make it ideal for monitoring and controlling dynamic processes such as downstream processing.</p><p>This study demonstrates a real-time methodology for accurately quantifying formulation excipients in the dynamic ultrafiltration/diafiltration (UF/DF) process using the <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2233"><strong>Thermo Scientific™ MarqMetrix™ All-In-One Process Raman Analyzer</strong></a> (Figure 1). In addition, this study also illustrates a case where process Raman was able to provide real-time information on buffer quality.</p><h4><strong>Results&nbsp;</strong></h4><p>The Partial Least Squares (PLS) models for L-histidine, L-arginine, and sucrose were initially tested using seven independent samples collected on three different process Raman analyzers. Data were mathematically processed to standardize spectra across instruments before applying the models. All the spectra were interpolated to have a common x-axis by equally spacing the 2048 pixels across 60 to 3250 cm-1 Raman shift, followed by relative y-axis standardization using the SRM fluorescence data as described in the NIST standardization protocol.² Figure&nbsp;3 shows the correlation plot of predicted versus reference values for L-histidine, L-arginine, and sucrose for the validation samples. A correlation coefficient of over 95% and a root means square error (RMSE) of less than 5% of the reference value for calibration, cross-validation, and prediction across three instruments demonstrate the reliability of process Raman to accurately predict the concentrations of these excipients, as well as easy model transferability.</p><h4><strong>Conclusion</strong></h4><p>This work, combined with our previous demonstrations of accurate in-line protein quantification during UF/DF processes,⁷, ⁸ clearly highlights the value of process Raman for downstream process monitoring. Raman spectroscopy allows for the simultaneous measurement of multiple critical process parameters (CPPs) with a single scan. These findings establish process Raman as a PAT tool with unparalleled benefits compared to other analytical methods.&nbsp;</p><p>Simultaneous measurement of protein and excipient concentrations not only allows tighter process control but also opens opportunities for automating downstream processing.&nbsp;</p><p>The ability of process Raman to provide real-time insights into buffer quality before its use in UF/DF runs offers substantial value by preventing batch failures. This capability enhances quality control, making Raman spectroscopy an essential tool for integration as an in-line sensor to improve downstream process monitoring, control, and automation.</p>

News from LabRulezICPMS Library - Week 38, 2026

Article

Application

Poster

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Dapoxetine analysis

Targeted HPLC analysis of dapoxetine in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The Dapoxetine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of dapoxetine in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About Dapoxetine</strong></h4><p>Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) developed for on-demand use. It increases serotonin activity in the central nervous system and is used in some countries for the treatment of premature ejaculation.</p><p>Dapoxetine is marketed under names such as Priligy and EJ-30. Its pharmacological profile differs from longer-acting SSRIs commonly used in the treatment of depression and anxiety disorders.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of dapoxetine</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound:</strong> Dapoxetine</li><li><strong>Other names:</strong> EJ-30, Priligy</li><li><strong>CAS number: </strong>119356-77-3</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 2 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders: </strong>10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for dapoxetine. It does not automatically screen the sample for other SSRIs, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of dapoxetine required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GCMS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

Sildenafil analysis

Targeted HPLC analysis of sildenafil in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The Sildenafil Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sildenafil in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About Sildenafil&nbsp;</strong></h4><p>Sildenafil, widely known under the trade name Viagra, is an orally active phosphodiesterase type 5 (PDE5) inhibitor. It inhibits PDE5 and enhances the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.</p><p>Sildenafil is clinically used primarily for the treatment of erectile dysfunction and is also used in specific formulations for pulmonary arterial hypertension.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of sildenafil</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound: </strong>Sildenafil</li><li><strong>Other name:</strong> Viagra</li><li><strong>CAS number:</strong> 139755-83-2</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 2 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders: </strong>10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for sildenafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of sildenafil required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GCMS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

Tadalafil Analysis

Targeted HPLC analysis of tadalafil in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The Tadalafil Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of tadalafil in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About Tadalafil</strong></h4><p>Tadalafil, widely known under the trade name Cialis, is an orally active phosphodiesterase type 5 (PDE5) inhibitor. It inhibits PDE5 and supports the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.</p><p>Tadalafil is clinically used primarily for the treatment of erectile dysfunction and is also used for conditions such as benign prostatic hyperplasia and pulmonary arterial hypertension.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of tadalafil</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound: </strong>Tadalafil</li><li><strong>Other name: </strong>Cialis</li><li><strong>CAS number: </strong>171596-29-5</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 2 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders: </strong>10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for tadalafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of tadalafil required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GCMS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

Vardenafil analysis

Targeted HPLC analysis of vardenafil in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The Vardenafil Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of vardenafil in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About Vardenafil</strong></h4><p>Vardenafil, marketed under names such as Levitra, Staxyn, and Vivanza, is an orally active phosphodiesterase type 5 (PDE5) inhibitor. It inhibits PDE5 and supports the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.</p><p>Vardenafil is clinically used for the treatment of erectile dysfunction. It belongs to the same pharmacological class as <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2519"><strong>sildenafil</strong></a>, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2520"><strong>tadalafil</strong></a>, and <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2517"><strong>avanafil</strong></a>.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of vardenafil</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound: </strong>Vardenafil</li><li><strong>Other names: </strong>Levitra, Staxyn, Vivanza</li><li><strong>CAS number: </strong>224785-90-4</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 2 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders: </strong>10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for vardenafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of vardenafil required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GC–MS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

Sildenafil/Tadafil blend analysis

Targeted HPLC analysis of sildenafil and tadalafil blends in pills, tablets, and capsules, confirming identity and determining the amount of both compounds.

<p><strong>The Sildenafil/Tadalafil Blend Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sildenafil and tadalafil in combined oral dosage forms.</strong></p><p>The analysis is suitable for pills, tablets, and capsules containing both compounds, with individual results reported in milligrams per tablet or capsule.</p><h4><strong>About Sildenafil and Tadalafil</strong></h4><p>Sildenafil and tadalafil are orally active phosphodiesterase type 5 (PDE5) inhibitors. Both compounds inhibit PDE5 and support the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.</p><p>Although they belong to the same pharmacological class, sildenafil and tadalafil differ in their pharmacokinetic profiles and duration of action. This analysis is specifically designed for products containing both compounds in a single formulation.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of sildenafil and tadalafil</li><li>Suitable for combined pills, tablets, and capsules</li><li>Simultaneous analysis of both target compounds</li><li>Analysis by HPLC</li><li>Results reported individually for sildenafil and tadalafil</li><li>Results reported in mg per tablet or capsule</li><li>Minimum sample amount of three tablets or capsules</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compounds:</strong> Tadalafil and Sildenafil</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation:</strong> 2 mg</li><li><strong>Result format: </strong>mg per tablet or capsule</li><li><strong>Minimum sample amount: </strong>Three tablets or capsules</li><li><strong>Average turnaround time: </strong>7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for products containing sildenafil and tadalafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>The minimum amount of each target compound required for evaluation is 2 mg. Samples containing lower amounts may not be reliably evaluated within the standard scope of the analysis.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.cz/products/2525"><strong>GCMS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

2,4-Dinitrophenol (DNP) Analysis

Targeted HPLC analysis of 2,4-dinitrophenol (DNP) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

<p><strong>The 2,4-Dinitrophenol (DNP) Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of 2,4-dinitrophenol in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About 2,4-Dinitrophenol (DNP)</strong></h4><p>2,4-Dinitrophenol (DNP) is a synthetic chemical compound that acts as an uncoupler of oxidative phosphorylation, disrupting normal cellular energy production and increasing heat generation.</p><p>DNP has historically been investigated for several industrial and biological applications but is highly toxic and is not approved as a weight-loss drug. Exposure can cause serious and potentially life-threatening adverse effects.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of 2,4-dinitrophenol (DNP)</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound: </strong>2,4-Dinitrophenol</li><li><strong>Other name: </strong>DNP</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 20 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders: </strong>5%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for 2,4-dinitrophenol (DNP). It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of DNP required for evaluation is 20 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li><li>DNP is a highly toxic compound. Laboratory analysis should not be interpreted as confirmation that a product is safe for human consumption.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GCMS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

5-Amino-1-methylquinolinium Analysis

Targeted HPLC analysis of 5-Amino-1-methylquinolinium in pills, tablets, capsules, and raw API powders for identity and amount determination.

<p><strong>The 5-Amino-1-methylquinolinium Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of 5-Amino-1-methylquinolinium in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by mass-by-mass purity in %. Please note that 5-Amino-1-methylquinolinium is not a peptide, and peptide purity is therefore not determined.</p><h4><strong>About 5-Amino-1-methylquinolinium</strong></h4><p>5-Amino-1-methylquinolinium, also known as 5A1MQ or 5-Amino-1MQ, is a small-molecule research compound investigated as an inhibitor of nicotinamide N-methyltransferase (NNMT). It is not a peptide.</p><p>NNMT is an enzyme involved in nicotinamide and cellular methylation metabolism. 5-Amino-1-methylquinolinium has been studied primarily in preclinical research related to cellular metabolism and adipose tissue biology.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of 5-Amino-1-methylquinolinium</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format reported as purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound:</strong> 5-Amino-1-methylquinolinium</li><li><strong>Other names: </strong>5A1MQ, 5-Amino-1MQ</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>5-Amino-1-methylquinolinium is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for 5-Amino-1-methylquinolinium. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances unless an additional screening service is ordered.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li>Iodide/Chloride Analysis</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526"><strong>CHNS Mass Report</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>LCMS Screening For Peptide Contamination</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

AICAR analysis

Targeted HPLC analysis of AICAR in finished lyophilised vials and raw API powders, confirming identity and determining the amount of the compound.

<p><strong>The AICAR Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of AICAR in finished lyophilised vials and raw active pharmaceutical ingredient (API) powders.</strong></p><p>For finished vials, results are reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). AICAR is not a peptide, and peptide purity is therefore not determined as part of this analysis.</p><h4><strong>About AICAR</strong></h4><p>AICAR is a small-molecule research compound widely used in studies of cellular energy metabolism and AMP-activated protein kinase (AMPK) signalling. After cellular uptake, AICAR riboside can be phosphorylated to ZMP, an AMP analogue that can activate AMPK.</p><p>AICAR has been investigated extensively in preclinical research examining metabolic regulation, glucose and lipid metabolism, and cellular responses to changes in energy availability. Its effects are not exclusively mediated through AMPK, and additional AMPK-independent mechanisms have also been described.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of AICAR</li><li>Suitable for finished lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for finished vials reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powder</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound:</strong> AICAR</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Result format for finished vial: </strong>mg per vial</li><li><strong>Alternative result format: </strong>Purity in % (m/m)</li><li><strong>Minimum sample amount for finished vial: </strong>One whole unopened vial with lyophilisate</li><li><strong>Minimum sample amount for raw API powder:</strong> 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>AICAR is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For finished products, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522"><strong>Endotoxin Analysis</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526"><strong>CHNS Mass Report</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>LCMS Screening For Peptide Contamination</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527"><strong>Sterility Testing</strong></a> (<span>TAMC and TYMC)</span></li><li>Additional Laboratory Report</li></ul>

BAC Water (Benzyl Alcohol) Analysis

HPLC analysis of benzyl alcohol in bacteriostatic water, including confirmation and concentration determination in mg/ml.

<p><strong>The BAC Water (Benzyl Alcohol) Analysis is a targeted laboratory test designed to confirm the presence and determine the concentration of benzyl alcohol in bacteriostatic water.</strong></p><p>The analysis is performed by HPLC, with results reported in milligrams of benzyl alcohol per millilitre of sample.</p><h4><strong>About Benzyl Alcohol</strong></h4><p>Benzyl alcohol is an aromatic alcohol commonly used as a preservative in pharmaceutical and laboratory formulations. In bacteriostatic water, it is added to help inhibit microbial growth after a vial has been opened.</p><p>This analysis specifically determines the concentration of benzyl alcohol in the submitted liquid sample.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of benzyl alcohol</li><li>Designed for bacteriostatic water and similar liquid samples</li><li>Analysis by HPLC</li><li>Results reported in mg/ml</li><li>Minimum concentration for evaluation: 1 mg/ml</li><li>Minimum sample amount: 1 ml</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound: </strong>Benzyl Alcohol</li><li><strong>Testing method:</strong> HPLC</li><li><strong>Minimum concentration of target compound for evaluation: </strong>1 mg/ml</li><li><strong>Result format:</strong> mg/ml</li><li><strong>Minimum sample amount:</strong> 1 ml</li><li><strong>Average turnaround time: </strong>7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for benzyl alcohol in liquid samples. It does not automatically screen the sample for other preservatives, active compounds, contaminants, or undeclared substances.</li><li>Samples containing less than 1 mg/ml benzyl alcohol may not be reliably evaluated within the standard scope of the analysis.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522"><strong>Endotoxin Analysis</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GC–MS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527"><strong>Sterility Testing</strong></a> (<span>TAMC and TYMC)</span></li></ul>

BAM-15 analysis

Targeted HPLC analysis of BAM-15 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The BAM-15 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of BAM-15 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). BAM-15 is not a peptide, and peptide purity is therefore not determined as part of this analysis.</p><h4><strong>About BAM-15</strong></h4><p>BAM-15 is a small-molecule research compound that acts as a mitochondrial uncoupler. It increases proton transport across the inner mitochondrial membrane, thereby uncoupling nutrient oxidation from ATP production and altering cellular energy metabolism.</p><p>BAM-15 has been investigated mainly in preclinical research focused on mitochondrial function, energy expenditure, glucose and lipid metabolism, and related metabolic processes</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of BAM-15</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound: </strong>BAM-15</li><li><strong>Other name: </strong>BAM15</li><li><strong>Testing method:</strong> HPLC</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Alternative result format: </strong>Purity in % (m/m)</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders: </strong>200 mg</li><li><strong>Average turnaround time: </strong>7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>BAM-15 is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for BAM-15. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances unless an additional screening service is ordered.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>LCMS Screening For Peptide Contamination</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

Products focused on HPLC - page 8

Related content

News from LabRulezICPMS Library - Week 38, 2026

News from LabRulezLCMS Library - Week 38, 2026

News from LabRulezGCMS Library - Week 38, 2026